Privacy Policy
Contact
Clinical Laserthermia Systems Americas Inc.
3 Park Plaza, Suite 1700
Irvine, CA 92614 USA
Phone: +1 (949) 504-5440
E-mail: contact-us@clinicallaser.com
©Copyright 2024 CLS AB. All rights reserved.
MM-2022-026-US/Rev3
Focal laser ablation provides a minimally invasive treatment that targets and ablates (destroys) only specific parts of glands, organs, or other tissue needing treatment, while preserving the surrounding and remaining tissue. This generally produces faster recovery, fewer side effects, and less pain and discomfort for patients that may not be good candidates or are inoperable for traditional open surgery*.
CLS AB is an innovative medical device company within healthcare technology and therapy. With people in mind, we are at the forefront of developing more precise, more effective interventional healthcare solutions.
Our TRANBERG™ systems marketed in the US by CLS Americas provide minimally invasive alternatives to traditional treatments and are FDA 510(k) cleared.
Focal therapy using laser ablation is a growing treatment option for patients with prostate cancer. It is an effective method that treats the tumor locally, saving healthy tissue.
Patient Focused
Our driving force is to design and develop tools for treatment of severe diseases, such as cancer, in a precise and careful way. It is from this perspective we have developed the TRANBERG™ Thermal Therapy System for image-guided focal laser ablation.
Through research by our co-founder, professor Karl-Göran Tranberg, CLS has gained significant knowledge and experience with treating/killing cancer tumors using laser ablation under image guidance.
Today, our TRANBERG™ Thermal Therapy System is optimized for minimally invasive focal therapy of soft tissue and used to treat patients with localized prostate cancer.
Last week we joined the 2024 Congress of Neurological Surgeons (CNS) meeting in Houston where our partner ClearPoint Neuro, Inc. exhibited the ClearPoint Prism® Neuro Laser Therapy System, powered by CLS. In addition to good booth traffic and customer discussions, we also took part in the scientific program providing the latest updates on the use of Laser Interstitial Thermal Therapy (LITT) in neurosurgery.
For the first time results from the CLS-sponsored study at Skåne University Hospital (SUS) will be presented and discussed during an international scientific congress. We are happy to share the abstract OP033 “Laser interstitial thermal therapy using an uncooled laser catheter in a diagnostic MR suite” by Dr Hjalmar Bjartmarz et al.
Since CLS´s laser ablation system for neurosurgery was cleared by the FDA in September last year development has progressed rapidly. But how does it actually work? We explain in this news post.
*All the focal therapies report low rates of complications, and high rates of continence and erectile function preservation. Klotz et al. Curr Opin Urol. (2020).
Welcome to Clinical Laserthermia Systems.
Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!
Please choose your country or region
Clinical Laserthermia Systems Americas Inc.
3 Park Plaza, Suite 1700
Irvine, CA 92614 USA
Phone: +1 (949) 504-5440
E-mail: contact-us@clinicallaser.com
©Copyright 2024 CLS AB. All rights reserved.
MM-2022-026-US/Rev3